$79.50
0.971.24%
Ult. Agg.: Oct 14, 1:32 PM
Kiniksa Pharmaceuticals (KNSA) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Kiniksa Pharmaceuticals (KNSA) ha pubblicato l'ultima guidance il luglio 28, 2026 per fiscal year 2026. La società ha previsto un fatturato pari a $980M - $995M per il periodo.
Rispetto alle previsioni precedenti, Kiniksa Pharmaceuticals ha modificato le sue previsioni di fatturato da un intervallo precedente di .
Kiniksa Pharmaceuticals ha pubblicato {{revenueDirection}} aggiornamenti delle previsioni tra il {{revenuePriorRange}} e il Kiniksa Pharmaceuticals. 7
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.30 | $0.16 | $0.35 | $0.35 |
| Actual | $0.30 | $0.27 | $0.17 | $0.23 |
| Surprise | 0.00% | +68.8% | -51.4% | -34.3% |
| Revenue | ||||
| Estimate | $226.7M | $205.6M | $200.9M | $166.8M |
| Actual | $243.6M | $214.3M | $202.1M | $180.9M |
| Surprise | +7.47% | +4.23% | +0.60% | +8.40% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $0.33 | $0.31 | $0.47 | $0.57 |
| Revenue | ||||
| Consensus | $259.6M | $276.4M | — | — |
| Trimestre fiscale | Data segnalata | EPS effettivo | EPS stimato | Sorpresa% |
|---|---|---|---|---|
| Q2 | Jul 28, 2026 | $0.30 | $0.30 | 0.00 % |
| Q1 | Apr 28, 2026 | $0.27 | $0.16 | 68.8 % |
| Q4 | Feb 24, 2026 | $0.17 | $0.35 | -51.4 % |
| Q3 | Oct 28, 2025 | $0.23 | $0.35 | -34.3 % |
| Trimestre fiscale | Data segnalata | Entrate effettive | Entrate stimate | Sorpresa% |
|---|---|---|---|---|
| Q2 | Jul 28, 2026 | $243.60M | $226.66M | 7.47 % |
| Q1 | Apr 28, 2026 | $214.30M | $205.59M | 4.23 % |
| Q4 | Feb 24, 2026 | $202.13M | $200.93M | 0.60 % |
| Q3 | Oct 28, 2025 | $180.86M | $166.84M | 8.40 % |